Publications by authors named "I Rubino"
The global tuberculosis (TB) epidemic affected 10 million people and caused 1.3 million deaths in 2022 alone. Multidrug-resistant TB is successfully treated in less than 60% of cases by long, expensive and aggressive treatments.
View Article and Find Full Text PDFArticle Synopsis
- - Ongoing assessment in postapproval studies for Alzheimer's disease aims to track disease progression and evaluate the effectiveness and safety of treatments in real-world scenarios.
- - The study faces challenges due to differences in data collection methods across various centers and the diversity of patients compared to those in clinical trials.
- - Key design elements for these studies include specifying aims and objectives, identifying study populations, and establishing consistent methods for measuring cognition, function, safety, and quality of life.
Article Synopsis
- Alzheimer's disease (AD) shows variability in how patients respond to amyloid beta removal therapy, impacting individual treatment benefits.
- A study utilized random forest models on the EMERGE trial to create an individual-level treatment response (ITR) score, highlighting significant differences in treatment effects among patients.
- Findings revealed that the top 25% of responders had distinct characteristics, such as lower hippocampal volume and more advanced disease, suggesting that precision medicine approaches could enhance future AD research and treatment strategies.*
Introduction: Whether the reduction in brain amyloid beta (Aβ) plaque alone may substantially slow cognitive and functional decline in patients with dementia or mild cognitive impairment due to Alzheimer's disease (AD) remains debated.
Methods: An instrumental variable meta-analysis was performed to infer the effect of change in positron emission tomography (PET)-measured Aβ standardized uptake value ratio (SUVR) on cognitive and functional decline.
Results: Pooling data from 16 randomized trials demonstrates that each 0.